Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — FY2020 Earnings Presentation
43 slides from Pt Prodia Widyahusada Tbk's earnings presentation, 2021
Slide 1: FY2020 Results Update
FY2020 Results Update
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: List of Figures
List of Figures Corporate Overview 04 Near Term and Long Term Strategy 18 Revenue 38 Company Highlight 05 Network Expansion Plan 19 Financial Update 39 Company History 06 Leader in Next Gen Technology 20 Gross Profit and Net Income 40 Shareholder Composition 07 Sustainability Highlights 21 COGS and
Slide 4: Corporate Overview
Corporate Overview 1
Slide 5: Company Highlight
IDR 1.87 Trillion • Established in 1973 with strong track record for more than 47 years experiences in FY2020 Revenue Clinical Lab Industry • Pioneer and the leading clinical laboratory >3.06 Million testing Company with the most recognized Brand in Indonesia • Largest private independent clinical l
Slide 6: Strong Track Record in Clinical Laboratory Testing
Strong Track Record in Clinical Laboratory Testing The first private lab in Indonesia that Received SMK3 accreditation and using fully automated Cobas 6800 Established professional OHSAS 2015, along with the Award Established Prodia for RT-PCR COVID-19 testing management team as "Diagnostic
Slide 7: Shareholder Composition
Shareholder Composition PT Prodia Utama Bio Majesty Pte. Ltd. Public 57% 18% 25% Contract Research, therapy Distributor for Research and banking of healthcare Organization stem cell products PT Prodia Widyahusada Tbk Occupational In Vitro Health Diagnostics Nationwide Outlet Network across Indonesia
Slide 8: Market Overview
Market Overview 2
Slide 9: Indonesia Economic Outlook
Indonesia Economic Outlook 4.0% – 5.0% Indonesia’s GDP Growth Projection for 2021 Indonesia’s economic recovery and improvement in 2021 GDP Growth Projection 2021 will be supported by the Indonesia World effectiveness of Indonesia’s Govt’ 5.0% N/A COVID-19 pandemic World Bank 4.4% 4.0% containment e
Slide 10: Investment Highlight
Investment Highlight 3
Slide 11: 1. Largest Network & Market Share in Independent Clinical Lab Industry
1. Largest Network & Market Share in Independent Clinical Lab Industry Market Share by Revenue Prodia vs Total Independent Labs Independent Clinical Labs (2018 & 2019) (Billion IDR) 3YRS CAGR 8.3% 38.8% 39.2% 4,551 3YRS CAGR 4,222 3,883 9.1% 2018 26.9% 2019 28.2% 1,744 1,466 1,600 33.0% 33.9% 2017 2
Slide 12: 2. Strong Operational Track Record
2. Strong Operational Track Record VISITS REVENUE CAGR CAGR 5.4% 8.4% Prodia has generated continuous revenue growth 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 and increasing number of visits that supported REVENUE PER VISIT Company’s profitability EBITDA CAGR 2.8% CAGR 21.5% 2016 2017 2018 2
Slide 13: 3. Comprehensive Service Offering with Multiple Customer Segments
3. Comprehensive Service Offering with Multiple Customer Segments Routine Testing Non-Laboratory Testing Specialty Clinics One-stop shop, offering the most Esoteric Testing Referral Lab Services Doctor Consultation comprehensive Predictive, Preventive, General Medical Preventive Treatment range of c
Slide 14: 4. Scalable Hub and Spoke Business Model
4. Scalable Hub and Spoke Business Model 4 Referral Labs in Jakarta, Surabaya, Medan, Makassar Significant Economies of Scale Achieved “Hub and spoke” model Centralized information Prodia Clinical Labs, offers scalable platform Prodia Referral with integrated IT Hospitals and Other Clinics platform
Slide 15: 5. Strong Relationship with Medical Community
5. Strong Relationship with Medical Community Strong relationships through the work of more Introduced new tests, such as NIPT ProSafe, Amino Acid Profile, than 500 Marketing and Laboratory Fatty Acid Profile, CArisk, DIArisk, Liquid biopsy EGFR Mutation, New Information Service personnel Born Scree
Slide 16: 6. Experienced Senior Leadership and Management Team
6. Experienced Senior Leadership and Management Team Professional Management Team with Strong Track Record in Delivering Superior Growth and Innovation Years of Years of Years of Years of Years of 48 Experience 48 Experience 38 Experience 32 Experience 34 Experience Andi Gunawan Endang Scott Andrew
Slide 17: Growth Strategy
Growth Strategy 4
Slide 18: Growth Strategy
Growth Strategy Expand our presence and grow Strengthen digital capabilities our network of outlets in both to enable business growth physical and digital channel in Indonesia Develop data & analytics A Near-term capabilities to create business values Upgrade existing clinical laboratories to provid
Slide 19: Prodia's Network Expansion Plan 2016 - 2021
Prodia’s Network Expansion Plan 2016 - 2021 1 2 3 4 Expand Network Upgrade Enhance Focus on of Outlets Clinical Labs Operating Quality 31 regional referral labs Upgrade up to 39 Efficiency clinical labs to PHC3 Clinics Up to 33 additional clinical labs over next five years 24 Clinical Lab Improvemen
Slide 20: Leader in Next Generation Technology
Leader in Next Generation Technology Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Separation Next Generation Diagnostic Science Laboratory Laboratory Laboratory Anatomical Advance Pathology Immunology Laboratory Laboratory Personalized Treatment The Concept of Precision Me
Slide 21: 2020 Sustainability Highlights
2020 Sustainability Highlights The Prodia Education & Scholarship, Education Research Institute Women’s Leadership & Training (PERI) • Scholarships for • The presence of 5 women in the Board of Directors • Training for Employees researchers for Diploma, and Commissioners (5 of 10 BOD/C or 50%) • The
Slide 22: Response to COVID-19 Pandemic
Response to COVID-19 Pandemic Develop COVID-19 Related Test: PCR & Antibody testing Expand More Collaboration and Partnership: More Hospital Referral especially for COVID-19 Create New Ways of Service: test and for Swab Sampling Cleanliness, Safety, Convenience Revisit Budget and Strategy: Broaden A
Slide 23: Response to COVID-19 Pandemic
Response to COVID-19 Pandemic Mid March 2020 April – June 2020 2H2020, and post COVID-19 2H2020, and post COVID-19 UNPRECEDENTED SHOCK SURVIVAL MODE REBOUND PHASE NEXT NORMAL Commit to deliver service & business Manage Lab Facilities & Enhance Lab Equipment Collaborating & Partnership BCP Ta
Slide 24: Response Capacity
Response Capacity Our Agility & Contribution during COVID-19 Pandemic The first positive confirmed BCP COVID- case of Covid-19 in Indonesia 19: Activated Guidelines: 1) Determination of COVID-19 Impact by President Joko Widodo on on 17 March 2020 Zones & Actions Done March 2nd, 2020. 2) Concern for
Slide 25: Our Contribution to Society
Our Contribution to Society MCU for medical staff at “Rumah Sakit Darurat Wisma Atlet” CSR Program : 1000 donation of Rapid Test Antibody (collaboration with Hospitals) Became one of the official network laboratories of BNPB Actively become Webinar Organizer for Customer Education Actively coordinat
Slide 26: More than 239K RT-PCR COVID-19
Prodia is the first Private Lab in Indonesia to use fully automated Cobas 6800 for RT- PCR COVID-19 testing and appointed as a part of the National Reference Laboratory Network for the RT-PCR COVID-19 Testing. More than 239K RT-PCR COVID-19 testing performed in 2020 26
Slide 27: Business Update
Business Update 5
Slide 28: Deliver Solution for Customer Needs
DELIVER SOLUTION FOR CUSTOMER NEEDS Respond to People Behavior Changing and Customer’s Voice Services & Lab Online Marketing Product Lab Testing In Facilities and Education Innovation COVID-19 Pandemic Activities • Prodia Mobile • Digital • Complete Testing from • COVID-19 Testing • Home/Office Serv
Slide 29: Digital Transformation to Increase Customer Satisfaction
Digital Transformation to Increase Customer Satisfaction > > Prodia has enhanced its digital platform services New Prodia Mobile Ver. 3 – Launched in Jan 2021 29
Slide 30: New Innovation & Enhancement
Customer Centric Model eRegistration New Innovation & Enhancement Prodia in your Car Service Prodia Home Customer Service Centric Tele-Consultation Tele-Radiology • General Practitioners • Clinical Pathologists Tele-Health* • Internist • Clinical Nutritionist • Sport Medicine 30
Slide 31: Outlet Development
Outlet Development 2021 Outlet 2016-2020 Outlet Development Development Target 259 283 292 287 267 1-2 20 Clinical Labs POC Outlets 5 7 4** 4** 2 14 11 14 12 9 Total Outlet 130 128 122 103 1-2 1 118 Specialty Clinics Hospital Lab Hospital Labs Specialty Clinic 129 136 143 147* 148* POC Outlets Clini
Slide 32: 14 New Tests Launched in 2020
Predictive, Preventive & Targeted Diagnostic Pharmacogenomics Screening Therapy 1. NIPT (ProSafe) 28. Jak2 Mutation 41.Jak 2 Mutation 51. Warfarin Indiv Test 2. Telomere Analysis 29. Kidney Stone Analysis (FTIR) 42. Mutation EGFR (CYP2C9 & VCORC1 3. Vitamin A & E 30. AMA & ASMA IF 43. Mutation EGFR
Slide 33: COVID-19 Related Tests
COVID-19 Related Tests PRODIA SIAP MELAYANI Serologi Anti SARS-CoV-2 (Immunoassay) Mendeteksi antibodi yang terbentuk spesifik i -CoV- : SARS-CONZ2 RHATECRICOVID=S} terhadap infeksi SARS-CoV-2, Skrining & Konfirmasi COVID-19 Sekaligus Prodia Siap Melayani Anti SARS-CoV-2 Kuantitatif (S-RBD) Bermanfa
Slide 34: New Esoteric & Genomic Tests
New Esoteric & Genomic Tests 34
Slide 35: Marketing Activities
Marketing Activities Keep Communicating and Educating Customer Live Interviews More than 300 Webinars 35
Slide 36: Social Media Activation
Nov 2020 @prodia_lab 154K 151,1K OO
Slide 37: Social Media Activation
Social Media Activation © VouTube Fate nicl coca Emil Webinar Linked to YouTube HOME VIDEOS PLAYLISTS COMMUNITY CHANNELS ABour Uploads © PLAY ALL = sowrsy eee ee WEBINAR: Thyroid Disease in WEDINAR: Challenges in WEBINAR: Diagnosis & ‘Sinuat Koester Diagnosis and Management... Manajemen infeksi HIV.
Slide 38: FY2020 Revenue
FY2020 Revenue Revenue (Audited) Quarterly Revenue (Unaudited) in IDR Billion in IDR Billion FY16-FY20 CAGR +8.4% 2020 2019 2018 2017 2016 FY19-FY20 growth: +7.4% Q4 2020, • Revenue was 671.3 increased +7.4% mostly driven by 1,873.4 1,744.3 Q3 2020, hospital and 1,599.8 external referral 1,466.0 544
Slide 39: Financial Update
Financial Update 6
Slide 40: FY2020 Gross Profit & Net Income (Audited)
FY2020 Gross Profit & Net Income (Audited) Gross Profit (in IDR Billion) Net Income (in IDR Billion) FY16-FY20 CAGR +7.0% FY16-FY20 CAGR +21.2% FY19-FY20 FY19-FY20 growth +0.5% growth +27.8% 268.7 1,041.0 1,046.2 210.3 853.5 942.8 175.5 150.8 14.3% 55.8% 58.9% 59.7% 58.2% 10.3% 11.0% 12.1% 2017 2018
Slide 41: FY2020 COGS & OPEX (Audited)
FY2020 COGS & OPEX (Audited) COGS (in IDR Billion) OPEX (in IDR Billion) FY16-FY20 CAGR %COGS per sales +13.5% FY16-FY20 CAGR %OPEX per sales -7.2% FY19-FY20 %COGS per FY19-FY20 %OPEX per sales growth +17.6% sales growth -16.1% ,000 50.0% 1,000 70.0% 827 827 770 746 800 703.3 800 676 713 50 656.9 46
Slide 42: FY2020 Financial Summary (Audited)
FY2020 Financial Summary (Audited) (in IDR Bn) FY2020 FY2019 Change (in IDR Bn) FY2020 FY2019 Change Revenue 1,873.4 1,744.3 +7.4% Total Asset 2,232.0 2,010.9 +11.0% Gross Profit 1,046.2 1,041.0 +0.5% Total Equity 1,788.3 1,659.6 +7.8% EBIT 301.8 216.0 +39.7% EBT 339.1 264.8 +28.1% Net Income 268.7
Slide 43: Thank You!
Thank You! For more information : PT Prodia Widyahusada Tbk investor.relation@prodia.co.id Prodia Tower, Jl. Kramat Raya No. 150, Jakarta 10430, Indonesia Phone +6221-3144182 ext. 3774, 3775 www.prodia.co.id 43